Pulmatrix (PULM) Q2 Revenue Falls 100%
Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.
How this was made

The 30-second read
Why it matters
The revenue drop could signal underlying issues affecting product development or commercialization.
Market read
The news is highly relevant for biotech investors and traders focusing on Pulmatrix and similar companies.
What to watch
Company may have significant cash reserves or partnerships that mitigate financial impact.
Background
Pulmatrix specializes in inhalation delivery platforms; recent revenue collapse suggests operational or developmental setbacks.
Ticker impact
Primary focus due to the news about revenue decline.
Potential short-term decline; long-term impact uncertain without additional context.
The revenue drop is a factual, quantifiable event with immediate market implications, especially for a biotech company with limited revenue streams.
Market effects
Biotech sector may face increased scrutiny and volatility.
Limited regional impact; primarily affects US biotech stocks.
Low; specific to US biotech sector.
Counterpoint
The revenue decline may be due to one-time factors or strategic restructuring, potentially leading to future recovery.
Key entities
- CompanyPulmatrix Inc.
Biotech firm focusing on inhalation delivery platforms.
- AuthorJesterAI
Author of the news article.




